FindTrial
Sign In

Evaluate the non-interventional clinical study of Axicabtagene injection in the treatment of relapsed or refractory non-Hodgkin's lymphoma

Evaluate the non-interventional clinical study of Axicabtagene injection in the treatment of relapsed or refractory non-Hodgkin's lymphoma

Status
Recruiting
Phases
Phase 4
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100047990
Enrollment
Unknown
Registered
2021-06-28
Start date
2021-11-26
Completion date
Unknown
Last updated
2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Relapsed or Refractory large B cell lymphoma

Interventions

case group:Nil

Sponsors

Union Hospital of Tongji Medical College of Huazhong University of Science and Technology
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: r/r NHL subjects receiving Asilenxel Injection, Fosun Kite's immune cell therapy product, in a commercially certified Fosun Kite Research Center in China, included subjects who received products that met quality release standards or products that did not meet quality release standards (OSS) as recommended by the attending physician.

Exclusion criteria

Exclusion criteria: Not Applicable

Design outcomes

Primary

MeasureTime frame
overall Survival;best objective response rate;complete response;partial response;durable of response;progress-free survival;—

Countries

China

Contacts

Public ContactHu Yu, Wu Depei, Zhao Weili
dr_huyu@126.com+86 13986183871, +86 13951102021, +86 13512112076

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 9, 2026